This inventor holds 36 USPTO granted patents, plus 1 CIPO patent and 5 EPO patents, primarily in Factor Xa Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company. Active years: 1995-2013.
Location History:
- New London, PA (US) (1997 - 1998)
- Lincoln University, PA (US) (1995 - 2007)
- Doylestown, PA (US) (2005 - 2013)
Company Filing History:
14 out of 3,736 
9 out of 234 
7 out of 106 Years Active: 1995-2013
Areas of Expertise:
Title: John Matthew Fevig – Innovator in G Protein-Coupled Receptor Modulators
Introduction
John Matthew Fevig is an accomplished inventor based in Doylestown, PA, with an impressive portfolio of 36 patents. His work primarily focuses on the development of novel compounds that serve as G protein-coupled receptor modulators, particularly for the treatment of diseases that necessitate such therapies.
Latest Patents
Among his latest innovations are the patents titled "[6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists." These patents present new compounds designed as GPR119 G protein-coupled receptor modulators. These modulators are crucial in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. The structural entities in these patents might include stereoisomers, prodrugs, or pharmaceutically acceptable salts, with specific variables defined therein. Additionally, he holds a patent for “[6,5]-bicyclic GPR119 G protein-coupled receptor agonists,” further emphasizing his contributions to this essential area of medical research.
Career Highlights
John's career includes significant tenure at prominent pharmaceutical companies, notably at Bristol-Myers Squibb Company and Bristol-Myers Squibb Pharma Company. His work in these organizations has deeply influenced the research and development of compounds that target G protein-coupled receptors.
Collaborations
Throughout his career, John has collaborated with esteemed colleagues, including Mimi Lifen Quan and James Russell Pruitt. These collaborations have fostered a conducive environment for innovation, leading to advancements in the field of G protein-coupled receptor research.
Conclusion
John Matthew Fevig stands out as a leading inventor in the realm of G protein-coupled receptor modulators. His contributions through his numerous patents and collaborations with industry professionals underscore his commitment to advancing medical science and improving therapeutic outcomes for various diseases.